Regeneron Pharmaceuticals (REGN) closed at $904.35 on November 6, 2026, up 0.2% from the previous close, on volume of 885,340 shares (30-day average 812,428).
Data as of November 6, 2026.
6-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 29, 2026 | Seagull With Call Spread | 06-Nov-26750 P : 835 C : 880 C | 1,050 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 6, 2026. See the 10 largest for 30, 60 and 90 days
Democratic lawmakers seen probing Trump drug pricing deals come January
Seeking Alpha News (Fri, 6-Nov 12:13 PM ET)
Regeneron Updates Key PNH Combination Study: What REGN Investors Should Know
TipRanks (Fri, 6-Nov 11:30 AM ET)
Regeneron Advances ALN-CIDEB Into Phase 3 Liver Disease Study
TipRanks (Thu, 5-Nov 11:33 AM ET)
BofA adds TMUS, REGN to Value 10 list, leaves Growth 10 untouched
Seeking Alpha News (Wed, 4-Nov 11:42 AM ET)
How health care is on the ballot in the midterms
Seeking Alpha News (Tue, 3-Nov 12:13 PM ET)
TipRanks (Tue, 3-Nov 12:00 PM ET)
Regeneron and Sanofi Update Long-Term Pediatric Dupixent Study
TipRanks (Tue, 3-Nov 11:30 AM ET)
Regeneron Announces Investor Conference Presentations
Globe Newswire (Mon, 2-Nov 4:05 PM ET)
Regeneron posts 70% non-GAAP EPS growth as Sanofi collaboration revenue jumps 68% in Q3 2026
Market Chameleon (Fri, 30-Oct 4:01 AM ET)
Regeneron Reports Third Quarter 2026 Financial and Operating Results
Globe Newswire (Fri, 30-Oct 6:30 AM ET)
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
Regeneron Pharmaceuticals trades on the NASDAQ stock market under the symbol REGN.
As of November 6, 2026, REGN stock price climbed to $904.35 with 885,340 million shares trading.
REGN has a beta of -0.15, meaning it tends to be less sensitive to market movements. REGN has a correlation of 0.00 to the broad based SPY ETF.
REGN has a market cap of $93.55 billion. This is considered a Large Cap stock.
Last quarter Regeneron Pharmaceuticals reported $5 billion in Revenue and $20.07 earnings per share. This beat revenue expectation by $556 million and exceeded earnings estimates by $4.32.
In the last 3 years, REGN traded as high as $1,211.20 and as low as $476.49.
The top ETF exchange traded funds that REGN belongs to (by Net Assets): VTI, VOO, QQQ, IVV, SPY.
REGN has outperformed the market in the last year with a price return of +40.4% while the SPY ETF gained +10.8%. REGN has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +17.2% and +12.3%, respectively, while the SPY returned -4.1% and -3.2%, respectively.
REGN support price is $881.59 and resistance is $924.21 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that REGN shares will trade within this expected range on the day.
